NSAIDS/COXIBS for the treatment of musculoskeletal pain secondary to hemophilic arthropathy.

IF 2.3 4区医学 Q2 HEMATOLOGY Expert Review of Hematology Pub Date : 2025-01-01 Epub Date: 2024-12-04 DOI:10.1080/17474086.2024.2438237

E Carlos Rodriguez-Merchan, Hortensia De la Corte-Rodriguez

{"title":"NSAIDS/COXIBS for the treatment of musculoskeletal pain secondary to hemophilic arthropathy.","authors":"E Carlos Rodriguez-Merchan, Hortensia De la Corte-Rodriguez","doi":"10.1080/17474086.2024.2438237","DOIUrl":null,"url":null,"abstract":"Introduction: Cyclooxygenase-2 (COX-2) inhibitors (COXIBS) are considered a suitable option for the treatment of hemophilic arthropathy.Areas covered: The role of traditional non-steroidal anti-inflammatory drugs; (NSAIDS) and COXIBS in people with hemophilia (PWH) and in the non-hemophiliac population has been reviewed in order to know which of them is more advisable in PWH and whether they should be used as the first or second therapeutic step for the treatment of musculoskeletal pain (since there is a discrepancy between what is advised by the WFH and the WHO).Expert opinion: For the treatment of chronic musculoskeletal pain related to hemophilic arthropathy, it is reasonable to use as a first step a combination of oral paracetamol (650 mg per every 6 h) or metamizole (575 mg per every 6 h), one of the COXIBS (e.g. celecoxib 200 mg per once a day) and a proton pump inhibitor (e.g. omeprazole 20 mg per once a day). The possible side effects of COXIBS should never be forgotten. For the treatment of hemophilic arthropathy pain, the risk/benefit ratio of COXIBS should be carefully assessed on an individual basis, although they are more advisable than traditional NSAIDS.","PeriodicalId":12325,"journal":{"name":"Expert Review of Hematology","volume":" ","pages":"33-38"},"PeriodicalIF":2.3000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17474086.2024.2438237","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Cyclooxygenase-2 (COX-2) inhibitors (COXIBS) are considered a suitable option for the treatment of hemophilic arthropathy.

Areas covered: The role of traditional non-steroidal anti-inflammatory drugs; (NSAIDS) and COXIBS in people with hemophilia (PWH) and in the non-hemophiliac population has been reviewed in order to know which of them is more advisable in PWH and whether they should be used as the first or second therapeutic step for the treatment of musculoskeletal pain (since there is a discrepancy between what is advised by the WFH and the WHO).

Expert opinion: For the treatment of chronic musculoskeletal pain related to hemophilic arthropathy, it is reasonable to use as a first step a combination of oral paracetamol (650 mg per every 6 h) or metamizole (575 mg per every 6 h), one of the COXIBS (e.g. celecoxib 200 mg per once a day) and a proton pump inhibitor (e.g. omeprazole 20 mg per once a day). The possible side effects of COXIBS should never be forgotten. For the treatment of hemophilic arthropathy pain, the risk/benefit ratio of COXIBS should be carefully assessed on an individual basis, although they are more advisable than traditional NSAIDS.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

非甾体抗炎药/COXIBS治疗血友病关节病继发的肌肉骨骼疼痛。

环氧化酶-2 （COX-2）抑制剂（COXIBS）被认为是治疗血友病关节病的合适选择。涉及领域：传统非甾体类抗炎药的作用；（非甾体抗炎药）和COXIBS在血友病患者（PWH）和非血友病人群中的应用已经进行了回顾，以了解其中哪一种在PWH中更可取，以及它们是否应作为治疗肌肉骨骼疼痛的第一或第二治疗步骤（因为世界卫生组织和世界卫生组织的建议存在差异）。专家意见：对于与血友病关节病相关的慢性肌肉骨骼疼痛的治疗，合理的第一步是口服扑热热痛（650毫克/每6小时）或metamizole（575毫克/每6小时），COXIBS（例如塞来昔布200毫克/每天一次）和质子泵抑制剂（例如奥美拉唑20毫克/每天一次）之一的组合。COXIBS可能产生的副作用永远不应该被忘记。对于血友病关节病疼痛的治疗，尽管COXIBS比传统的非甾体抗炎药更可取，但在个体基础上应仔细评估其风险/获益比。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Expert Review of Hematology HEMATOLOGY-

CiteScore

4.70

自引率

3.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Advanced molecular research techniques have transformed hematology in recent years. With improved understanding of hematologic diseases, we now have the opportunity to research and evaluate new biological therapies, new drugs and drug combinations, new treatment schedules and novel approaches including stem cell transplantation. We can also expect proteomics, molecular genetics and biomarker research to facilitate new diagnostic approaches and the identification of appropriate therapies. Further advances in our knowledge regarding the formation and function of blood cells and blood-forming tissues should ensue, and it will be a major challenge for hematologists to adopt these new paradigms and develop integrated strategies to define the best possible patient care. Expert Review of Hematology (1747-4086) puts these advances in context and explores how they will translate directly into clinical practice.